These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38710241)

  • 1. Targeting LRP6: A new strategy for cancer therapy.
    Xue W; Zhu B; Zhao K; Huang Q; Luo H; Shou Y; Huang Z; Guo H
    Pharmacol Res; 2024 Jun; 204():107200. PubMed ID: 38710241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.
    Arensman MD; Nguyen P; Kershaw KM; Lay AR; Ostertag-Hill CA; Sherman MH; Downes M; Liddle C; Evans RM; Dawson DW
    Mol Cancer Res; 2015 Nov; 13(11):1509-19. PubMed ID: 26224368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.
    Lu W; Lin C; Li Y
    Cell Signal; 2014 Jun; 26(6):1303-9. PubMed ID: 24607787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
    Lu W; Lin C; King TD; Chen H; Reynolds RC; Li Y
    Cell Signal; 2012 Dec; 24(12):2291-6. PubMed ID: 22820499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.
    Yu S; Wang Z; Su Z; Song J; Zhou L; Sun Q; Liu S; Li S; Li Y; Wang M; Zhang GQ; Zhang X; Liu ZJ; Lu D
    BMC Complement Altern Med; 2018 Feb; 18(1):59. PubMed ID: 29444668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy.
    Rajagopal C; Lankadasari MB; Aranjani JM; Harikumar KB
    Pharmacol Res; 2018 Apr; 130():273-291. PubMed ID: 29305909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
    Wu W; Xue X; Chen Y; Zheng N; Wang J
    Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifaceted effects of LRP6 in cancer: exploring tumor development, immune modulation and targeted therapies.
    Li L; Zhao L; Yang J; Zhou L
    Med Oncol; 2024 Jun; 41(7):180. PubMed ID: 38898247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparagine: A key metabolic junction in targeted tumor therapy.
    Wang X; Gong W; Xiong X; Jia X; Xu J
    Pharmacol Res; 2024 Aug; 206():107292. PubMed ID: 39002867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
    Lu W; Li Y
    J Cell Biochem; 2014 Oct; 115(10):1799-807. PubMed ID: 24905570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
    Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex.
    Zhou L; Wang Z; Yu S; Xiong Y; Fan J; Lyu Y; Su Z; Song J; Liu S; Sun Q; Lu D
    J Pharmacol Exp Ther; 2020 Apr; 373(1):149-159. PubMed ID: 32015160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.
    Han D; Cao C; Su Y; Wang J; Sun J; Chen H; Xu A
    J Ethnopharmacol; 2016 Nov; 192():406-412. PubMed ID: 27649680
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Chen LJ; Lin XX; Guo J; Xu Y; Zhang SX; Chen D; Zhao Q; Xiao J; Lian GH; Peng SF; Guo D; Yang H; Shu Y; Zhou HH; Zhang W; Chen Y
    Int J Biol Sci; 2021; 17(14):3936-3953. PubMed ID: 34671210
    [No Abstract]   [Full Text] [Related]  

  • 17. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
    Shah K; Panchal S; Patel B
    Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
    Lernoux M; Schnekenburger M; Dicato M; Diederich M
    Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies.
    Wang Y; Xie Q; Tan H; Liao M; Zhu S; Zheng LL; Huang H; Liu B
    Pharmacol Res; 2021 Nov; 173():105702. PubMed ID: 34102228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
    Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
    Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.